164 related articles for article (PubMed ID: 38874196)
41. High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis.
Ergenc I; Gokcen P; Adali G; Tarik Kani H; Ozer Demirtas C; Gunduz F; Ataizi Celikel C; Yilmaz Y
Hepatol Forum; 2021 Jan; 2(1):20-25. PubMed ID: 35782891
[TBL] [Abstract][Full Text] [Related]
42. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC.
Liu L; Xie S; Teng YX; Deng ZJ; Chen K; Liu HT; Huo RR; Liang XM; Guo PP; Yang DL; Ma L; Xiang BD; Li LQ; Zhong JH
Front Oncol; 2021; 11():783339. PubMed ID: 35127490
[TBL] [Abstract][Full Text] [Related]
43. Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation.
Peleman C; Francque S; Berghe TV
EBioMedicine; 2024 Apr; 102():105088. PubMed ID: 38537604
[TBL] [Abstract][Full Text] [Related]
44. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database.
Vitale A; Svegliati-Baroni G; Ortolani A; Cucco M; Dalla Riva GV; Giannini EG; Piscaglia F; Rapaccini G; Di Marco M; Caturelli E; Zoli M; Sacco R; Cabibbo G; Marra F; Mega A; Morisco F; Gasbarrini A; Foschi FG; Missale G; Masotto A; Nardone G; Raimondo G; Azzaroli F; Vidili G; Oliveri F; Pelizzaro F; Ramirez Morales R; Cillo U; Trevisani F; Miele L; Marchesini G; Farinati F;
Gut; 2023 Jan; 72(1):141-152. PubMed ID: 34933916
[TBL] [Abstract][Full Text] [Related]
45. Unveiling the Role of the Fatty Acid Binding Protein 4 in the Metabolic-Associated Fatty Liver Disease.
Moreno-Vedia J; Girona J; Ibarretxe D; Masana L; Rodríguez-Calvo R
Biomedicines; 2022 Jan; 10(1):. PubMed ID: 35052876
[TBL] [Abstract][Full Text] [Related]
46. Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis.
Crane H; Eslick GD; Gofton C; Shaikh A; Cholankeril G; Cheah M; Zhong JH; Svegliati-Baroni G; Vitale A; Kim BK; Ahn SH; Kim MN; Strasser S; George J
Clin Mol Hepatol; 2024 Apr; ():. PubMed ID: 38623613
[TBL] [Abstract][Full Text] [Related]
47. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
[TBL] [Abstract][Full Text] [Related]
48. Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study.
Yun B; Ahn SH; Oh J; Yoon JH; Kim BK
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291786
[TBL] [Abstract][Full Text] [Related]
49. Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma.
Sun YD; Zhang H; Li YM; Han JJ
Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189086. PubMed ID: 38342420
[TBL] [Abstract][Full Text] [Related]
50. The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions.
Ugonabo O; Udoh US; Rajan PK; Reeves H; Arcand C; Nakafuku Y; Joshi T; Finley R; Pierre SV; Sanabria JR
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759769
[TBL] [Abstract][Full Text] [Related]
51. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study.
Lin YP; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Tsai MC
Front Oncol; 2022; 12():816472. PubMed ID: 35186751
[TBL] [Abstract][Full Text] [Related]
52. Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease.
Miao T; Lou X; Dong S; Zhang X; Guan W; Zhang Y; Li L; Yuan X; Ma D; Nan Y
J Hepatocell Carcinoma; 2024; 11():145-157. PubMed ID: 38260867
[TBL] [Abstract][Full Text] [Related]
53. Smoking Increases the Risk of Hepatocellular Carcinoma and Cardiovascular Disease in Patients with Metabolic-Associated Fatty Liver Disease.
Yoo JJ; Park MY; Cho EJ; Yu SJ; Kim SG; Kim YJ; Kim YS; Yoon JH
J Clin Med; 2023 May; 12(9):. PubMed ID: 37176776
[TBL] [Abstract][Full Text] [Related]
54. Sarcopenia Imperils Postoperative Long-Term Survival in HCC Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Propensity Score Matching Analysis.
Kong Q; Yi M; Teng F; Li H; Chen Z
J Hepatocell Carcinoma; 2023; 10():1367-1377. PubMed ID: 37605756
[TBL] [Abstract][Full Text] [Related]
55. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes.
Ito T; Nguyen MH
J Hepatocell Carcinoma; 2023; 10():413-428. PubMed ID: 36926055
[TBL] [Abstract][Full Text] [Related]
56. Sex Differences in the Impact of Metabolic Dysfunction-associated Fatty Liver Disease on the of Patients with Hepatocellular Carcinoma After Radical Resection.
Huang J; Wei S; Tang Y; Zhang Q; Luo H; Tang Z; Tang Y; Liu H; Huang W; Dong X; Yang J
J Cancer; 2023; 14(7):1107-1116. PubMed ID: 37215444
[No Abstract] [Full Text] [Related]
57. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
58. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
[TBL] [Abstract][Full Text] [Related]
59. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH).
Gallego-Durán R; Albillos A; Ampuero J; Arechederra M; Bañares R; Blas-García A; Berná G; Caparrós E; Delgado TC; Falcón-Pérez JM; Francés R; Fernández-Barrena MG; Graupera I; Iruzubieta P; Nevzorova YA; Nogueiras R; Macías RIR; Martín F; Sabio G; Soriano G; Vaquero J; Cubero FJ; Gracia-Sancho J
Gastroenterol Hepatol; 2022 Nov; 45(9):724-734. PubMed ID: 35248669
[TBL] [Abstract][Full Text] [Related]
60. From MAFLD to hepatocellular carcinoma and everything in between.
Bae SDW; George J; Qiao L
Chin Med J (Engl); 2022 Feb; 135(5):547-556. PubMed ID: 35191421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
